Innovation & Tech

Exo Receives $11.6 Million Grant for Offline AI Ultrasound

Exo received an $11.6 million Gates Foundation grant to develop a handheld ultrasound platform that combines silicon imaging with on-device AI and works without an internet connection.

By Daniel Okafor

3 min read

Exo Receives $11.6 Million Grant To Expand AI-Powered Ultrasound Access
Exo Receives $11.6 Million Grant To Expand AI-Powered Ultrasound AccessAhmadArdity / pixabay

What's News

  • Exo received an $11.6 million grant from the Gates Foundation.
  • The $11.6 million grant will support a multi-use handheld ultrasound system for frontline healthcare workers without specialized expertise.
  • Exo's platform combines silicon-based imaging hardware with real-time, on-device AI.
  • The AI operates on the device, so the system does not require an internet connection.
  • Exo identified four potential applications: diagnostic imaging, procedural guidance, therapy and patient monitoring.

By Daniel Okafor

The Gates Foundation has awarded Exo an $11.6 million grant to advance affordable diagnostic imaging technology in low- and middle-income countries. Exo said the funding will support development of a multi-use handheld ultrasound system for frontline healthcare workers who lack specialized ultrasound expertise.

Sandeep Akkaraju, Chief Executive Officer of Exo, said:

“By combining silicon imaging with on-device AI, we’re working to make ultrasound more affordable and easier for frontline healthcare workers to use. This funding will help us advance a platform designed for communities where access to imaging and specialist expertise is limited. We’re grateful to the Gates Foundation for its continued support.”

Akkaraju's statement ties the financing to three points: work to make ultrasound more affordable, easier use by frontline healthcare workers, and a platform designed for communities with limited imaging access and specialist expertise. He also thanked the Gates Foundation for its continued support.

Exo is developing the same core platform for two product routes. One centers on a handheld ultrasound device. The other places an imaging system inside equipment made by other manufacturers.

The contrast is concrete: Exo can pursue a complete device and a system for other makers' equipment. The award supports the shared technology base rather than a single scanner program. The shared platform links silicon-based imaging, on-device artificial intelligence, handheld devices and systems integrated into other manufacturers' equipment through a single grant-funded program spanning several product paths.

How does Exo make ultrasound work without an internet connection?

Exo's platform combines silicon-based imaging hardware with artificial intelligence. The AI guides image acquisition and interpretation in real time, Exo said. It operates directly on the device, so the system does not require an internet connection.

Exo says the design targets four barriers: equipment costs, imaging complexity, limited access to specialists and unreliable connectivity. The affordability goal responds to cost. On-device guidance responds to complexity. Real-time interpretation is designed to reduce specialist dependence. Local operation removes unreliable connectivity as a prerequisite.

In practice, the grant supports a workflow that links imaging hardware, operator guidance and interpretation on one device, with connectivity removed from the core chain.

What can the platform do?

Exo identifies four potential applications for the platform:

  • Diagnostic imaging
  • Procedural guidance
  • Therapy
  • Patient monitoring

Exo calls these potential uses. Exo's announcement provides no specifications, regulatory status or timetable for any one application. It also does not quantify how much of the $11.6 million will fund each use.

According to Exo, the four uses indicate the range for one imaging and artificial-intelligence base, spanning diagnosis, procedures, therapy and patient monitoring within the same grant-funded program.

What does the $11.6 million still leave unanswered?

The funding directly supports development work, according to Exo. Exo did not disclose the grant term, device price, regulatory timetable, clinical-performance target, manufacturing volume or first deployment market. Exo also did not name manufacturer partners for its integrated-system route.

Commercial scale remains unstated because Exo's announcement describes development, potential applications and a shared technology platform without a purchase order, distribution commitment or rollout commitment. Akkaraju sets the standard: affordability and easier frontline use where specialist expertise is scarce. The next test is deployed performance in the target countries: price, frontline usability and offline reliability. Deployment evidence will determine whether Exo can turn the shared architecture into a scalable medical-imaging product.

Source: pulse2.com

Share this article:

More from Daniel Okafor

Daniel Okafor

Show full bio

Correspondent covering money, funding and market shifts around entrepreneurship, startups and venture funding at Business Bearings.

2,538 articles

Related articles

« Previous article